Everest Organics Ltd. is a pharmaceutical company, which engages in the manufacture of bulk drugs. The company is headquartered in Hyderabad, Telangana. The company is involved in manufacturing of bulk drugs, such as Omeprazole, Ciprofloxacin, Dichloroflurobenzene, Naproxen, Benzimadizole. The Company’s API’s products include Pantoprazole Sodium Sesquihydrate USP/BP/EP/IP, Esomeprazole Magnesium Trihydrate-USP/BP/IP/EP, Esomeprazole Magnesium Trihydrate-USP/BP, Esomeprazole Magnesium Dihydrate, Omeprazole Powder-USP / BP/ EP/IP, Omeprazole Magnesium-IP/EP/USP and others. Its intermediates products include 2-Mercapto-5-Methoxy Benzimidazole (Omeprazole-Benzimidazole), 2-Chloro-Methyl-3,5-Dimethyl-4-Methoxy Pyridine HCL (Omeprazole Chloro Compound), Ammonium Sulphate, Sodium Nitrite and others. Its products under development include Sitagliptin, Vildagliptin, Ilaprazole, N-(5-Amino-2-Methylphenyl)-4-(3-Pyridyl)-2-Pyrimidineamine (Imatinib Intermediate), Lanso Sulphide and others.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.